• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Apria Announces Launch of Secondary Offering of Common Stock

    11/8/21 4:10:00 PM ET
    $APR
    Medical/Dental Instruments
    Health Care
    Get the next $APR alert in real time by email

    INDIANAPOLIS, Nov. 08, 2021 (GLOBE NEWSWIRE) -- Apria, Inc. (the "Company" or "Apria")  (NASDAQ:APR) announced today that a selling stockholder affiliated with Blackstone has commenced a secondary offering of 4,500,000 shares of Apria common stock. In connection with the offering, the selling stockholder intends to grant the underwriters a 30-day option to purchase up to an additional 675,000 shares of common stock.

    Apria is not offering any shares of its common stock and will not receive any net proceeds from the sale of common stock by the selling stockholder. Citigroup and Goldman Sachs & Co. LLC are acting as joint lead book-running managers for the offering. Citizens Capital Markets is acting as a co-manager for the offering.

    The offering of these securities will be made only by means of a prospectus. When available, copies of the preliminary prospectus relating to the offering may be obtained from: Citigroup Global Markets Inc., c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, by telephone at 1-800-831-9146 or by email at [email protected] or Goldman Sachs & Co. LLC, Attention: Prospectus Department, 200 West Street, New York, NY 10282, by telephone at 1-866-471-2526, by facsimile at 1-212-902-9316 or by email at [email protected].

    A registration statement, including a prospectus, which is preliminary and subject to completion, relating to these securities has been filed with the Securities and Exchange Commission (the "SEC"), but has not yet become effective. These securities may not be sold, nor may offers to buy be accepted, prior to the time that the registration statement becomes effective. This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

    About Apria

    Apria is a leading provider of integrated home healthcare equipment and related services in the United States, providing home respiratory therapy, obstructive sleep apnea treatment and negative pressure wound therapy. Its approximately 280 locations throughout the continental United States and Hawaii serve nearly 2 million patients each year. All of Apria's locations are accredited by The Joint Commission.        

    Forward-Looking Statements

    This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These statements include any statements regarding the proposed offering of Apria common stock and other non-historical statements. Forward-looking statements include all statements that do not relate solely to historical or current facts. In some cases, you can identify these forward-looking statements by the use of words such as "outlook," "believes," "expects," "potential," "continues," "may," "will," "should," "could," "seeks," "predicts," "intends," "trends," "plans," "estimates," "anticipates" or the negative version of these words or other comparable words. Such forward-looking statements are subject to various risks and uncertainties. Accordingly, there are or will be important factors that could cause actual outcomes or results to differ materially from those indicated in these statements. These factors include but are not limited to those described under "Risk Factors" in the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2020 and in the Company's Quarterly Report on Form 10-Q for the three months ended June 30, 2021, each as filed with the SEC, as such factors may be updated from time to time in the Company's periodic filings with the SEC. These factors should not be construed as exhaustive and should be read in conjunction with the other cautionary statements that are included in this press release and in the Company's filings with the SEC. Investors are urged to consider carefully the disclosure in the Company's filings with the SEC, which are accessible on the SEC's website at www.sec.gov. The Company undertakes no obligation to publicly update or review any forward-looking statement, whether as a result of new information, future developments or otherwise, except as required by law.

    Investor Contacts

    [email protected]

    Media Contacts

    [email protected]

    [email protected]



    Primary Logo

    Get the next $APR alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $APR

    DatePrice TargetRatingAnalyst
    1/11/2022$37.50Buy → Neutral
    UBS
    1/10/2022$39.00Buy
    Citigroup
    11/19/2021$39.00Buy
    Citigroup
    11/8/2021$43.00Buy
    Citigroup
    7/19/2021$32.00 → $29.00Buy → Neutral
    Goldman Sachs
    6/30/2021$33.00Buy
    Citigroup
    More analyst ratings

    $APR
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4: Walker Robert P. returned $192,450 worth of shares to the company (5,132 units at $37.50), closing all direct ownership in the company (tax liability)

      4 - Apria, Inc. (0001735803) (Issuer)

      3/29/22 4:31:49 PM ET
      $APR
      Medical/Dental Instruments
      Health Care
    • SEC Form 4: Apria Holdings Llc sold $532,031,812 worth of shares (14,187,515 units at $37.50)

      4 - Apria, Inc. (0001735803) (Issuer)

      3/29/22 4:31:15 PM ET
      $APR
      Medical/Dental Instruments
      Health Care
    • SEC Form 4 filed by Snyder Lynn Shapiro to satisfy withholding obligation

      4 - Apria, Inc. (0001735803) (Issuer)

      3/29/22 4:31:20 PM ET
      $APR
      Medical/Dental Instruments
      Health Care

    $APR
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Apria Announces Financial Results for Fourth Quarter and Full Year 2021

      INDIANAPOLIS, Feb. 28, 2022 (GLOBE NEWSWIRE) -- Apria, Inc. (the "Company" or "Apria") (NASDAQ:APR), a leading provider of integrated home healthcare equipment and related services in the United States, announced today financial results for the fourth quarter and full year ended December 31, 2021. As previously announced, the Company will not be hosting a conference call to discuss its financial results. "We reported solid fourth quarter financial results and 2021 was a good year for Apria. Our team did an excellent job operating and executing at a high level while navigating the challenges from the COVID-19 pandemic, as well as a major product recall and supply chain constraints. Fourth

      2/28/22 6:30:00 AM ET
      $APR
      Medical/Dental Instruments
      Health Care
    • Apria Announces Expiration of Hart-Scott-Rodino Waiting Period

      INDIANAPOLIS, Feb. 24, 2022 (GLOBE NEWSWIRE) -- Apria, Inc. (the "Company" or "Apria") (NASDAQ:APR), a leading provider of home medical equipment, supplies and related services in the United States, announced today that the waiting period has expired under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended, in connection with its previously announced transaction with Owens & Minor, Inc. The closing of the transaction remains subject to approval by holders of a majority of the Company's outstanding common stock and other customary closing conditions. About Apria Apria is a leading provider of integrated home healthcare equipment and related services in the United States,

      2/24/22 4:05:00 PM ET
      $APR
      Medical/Dental Instruments
      Health Care
    • Owens & Minor, Inc. Signs Definitive Agreement to Acquire Apria, Inc.

      Highly Complementary Transaction Expands Patient Direct Offering Year-One Accretion Across Key Financial Metrics and Free Cash Flow Enhancement Creates a Leading Platform for Future Growth Owens & Minor, Inc. ("Owens & Minor") (NYSE:OMI) and Apria, Inc. ("Apria") (NASDAQ:APR) today announced that the companies have entered into a definitive agreement pursuant to which Owens & Minor will acquire Apria for $37.50 in cash per share of common stock, representing an equity value of approximately $1.45 billion. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220110005291/en/ "I'm very excited about the acquisition of Apria, which wil

      1/10/22 6:00:00 AM ET
      $APR
      $OMI
      Medical/Dental Instruments
      Health Care
      Medical Specialities

    $APR
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Apria downgraded by UBS with a new price target

      UBS downgraded Apria from Buy to Neutral and set a new price target of $37.50

      1/11/22 6:43:54 AM ET
      $APR
      Medical/Dental Instruments
      Health Care
    • Citigroup resumed coverage on Apria with a new price target

      Citigroup resumed coverage of Apria with a rating of Buy and set a new price target of $39.00

      1/10/22 7:15:48 AM ET
      $APR
      Medical/Dental Instruments
      Health Care
    • Citigroup resumed coverage on Apria with a new price target

      Citigroup resumed coverage of Apria with a rating of Buy and set a new price target of $39.00

      11/19/21 7:12:27 AM ET
      $APR
      Medical/Dental Instruments
      Health Care

    $APR
    SEC Filings

    See more
    • SEC Form 15-12B filed by Apria Inc.

      15-12B - Apria, Inc. (0001735803) (Filer)

      4/8/22 10:10:58 AM ET
      $APR
      Medical/Dental Instruments
      Health Care
    • SEC Form 25-NSE filed by Apria Inc.

      25-NSE - Apria, Inc. (0001735803) (Subject)

      3/29/22 8:55:14 AM ET
      $APR
      Medical/Dental Instruments
      Health Care
    • SEC Form S-8 POS filed by Apria Inc.

      S-8 POS - Apria, Inc. (0001735803) (Filer)

      3/29/22 8:35:01 AM ET
      $APR
      Medical/Dental Instruments
      Health Care

    $APR
    Leadership Updates

    Live Leadership Updates

    See more
    • Apria Appoints Christopher G. Lee as Chief Accounting Officer

      INDIANAPOLIS, Oct. 04, 2021 (GLOBE NEWSWIRE) -- Apria, Inc. (the "Company" or "Apria") (NASDAQ:APR), a leading provider of home medical equipment, supplies and related services in the United States, announced today the appointment of Christopher G. Lee as Chief Accounting Officer, a newly created position. Mr. Lee will report to Debra Morris, Apria's Chief Financial Officer. Mr. Lee has 18 years of accounting and financial leadership experience. He joined Apria in February 2009 and has risen internally to his most recent role as Senior Vice President, Accounting and Finance. Prior to joining Apria, Mr. Lee was with Deloitte & Touche. Mr. Lee is a graduate of the University of California a

      10/4/21 8:00:00 AM ET
      $APR
      Medical/Dental Instruments
      Health Care

    $APR
    Financials

    Live finance-specific insights

    See more
    • Owens & Minor, Inc. Signs Definitive Agreement to Acquire Apria, Inc.

      Highly Complementary Transaction Expands Patient Direct Offering Year-One Accretion Across Key Financial Metrics and Free Cash Flow Enhancement Creates a Leading Platform for Future Growth Owens & Minor, Inc. ("Owens & Minor") (NYSE:OMI) and Apria, Inc. ("Apria") (NASDAQ:APR) today announced that the companies have entered into a definitive agreement pursuant to which Owens & Minor will acquire Apria for $37.50 in cash per share of common stock, representing an equity value of approximately $1.45 billion. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220110005291/en/ "I'm very excited about the acquisition of Apria, which wil

      1/10/22 6:00:00 AM ET
      $APR
      $OMI
      Medical/Dental Instruments
      Health Care
      Medical Specialities
    • Apria to Announce Third Quarter 2021 Financial Results

      INDIANAPOLIS, Oct. 21, 2021 (GLOBE NEWSWIRE) -- Apria, Inc. (the "Company" or "Apria") (NASDAQ:APR) announced today that it will release fiscal third quarter 2021 financial results on Thursday, November 4, 2021 after the market closes. In conjunction, the company will host a conference call to review results at 5:00 p.m. (ET) on the same day. Conference Call Details The conference call can be accessed by dialing (833) 362-0207 for U.S. participants, or (914) 987-7676 for international participants, referencing conference ID 4161279; or via a live audio webcast that will be available online at https://ir.apria.com/. A replay of the call will be available via webcast for on-demand listeni

      10/21/21 8:00:00 AM ET
      $APR
      Medical/Dental Instruments
      Health Care
    • Apria to Announce Second Quarter 2021 Financial Results

      INDIANAPOLIS, July 22, 2021 (GLOBE NEWSWIRE) -- Apria, Inc. (the "Company" or "Apria") (NASDAQ:APR) announced today that it will release fiscal second quarter 2021 financial results on Thursday, August 5, 2021 after the market closes. In conjunction, the company will host a conference call to review results at 5:00 p.m. (ET) on the same day. Conference Call Details The conference call can be accessed by dialing (833) 362-0207 for U.S. participants, or (914) 987-7676 for international participants, referencing conference ID # 5380517; or via a live audio webcast that will be available online at https://ir.apria.com/. A replay of the call will be available via webcast for on-demand listen

      7/22/21 4:05:00 PM ET
      $APR
      Medical/Dental Instruments
      Health Care

    $APR
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by Apria Inc. (Amendment)

      SC 13G/A - Apria, Inc. (0001735803) (Subject)

      4/8/22 4:04:00 PM ET
      $APR
      Medical/Dental Instruments
      Health Care
    • SEC Form SC 13G filed by Apria Inc.

      SC 13G - Apria, Inc. (0001735803) (Subject)

      3/10/22 5:01:54 PM ET
      $APR
      Medical/Dental Instruments
      Health Care
    • SEC Form SC 13G filed by Apria Inc.

      SC 13G - Apria, Inc. (0001735803) (Subject)

      2/14/22 4:06:09 PM ET
      $APR
      Medical/Dental Instruments
      Health Care